Cargando…
Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines
Many cancers have the tumor suppressor p53 inactivated by mutation, making reactivation of mutant p53 with small molecules a promising strategy for the development of novel anticancer therapeutics. The oncogenic p53 mutation Y220C, which accounts for approximately 100,000 cancer cases per year, crea...
Autores principales: | Baud, Matthias G.J., Bauer, Matthias R., Verduci, Lorena, Dingler, Felix A., Patel, Ketan J., Horil Roy, Deeptee, Joerger, Andreas C., Fersht, Alan R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editions Scientifiques Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986712/ https://www.ncbi.nlm.nih.gov/pubmed/29702446 http://dx.doi.org/10.1016/j.ejmech.2018.04.035 |
Ejemplares similares
-
A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C
por: Bauer, Matthias R, et al.
Publicado: (2019) -
Harnessing Fluorine–Sulfur Contacts and Multipolar
Interactions for the Design of p53 Mutant Y220C Rescue Drugs
por: Bauer, Matthias R., et al.
Publicado: (2016) -
Discovery of Nanomolar-Affinity
Pharmacological Chaperones
Stabilizing the Oncogenic p53 Mutant Y220C
por: Stephenson Clarke, Joseph R., et al.
Publicado: (2022) -
Targeting Cavity-Creating p53 Cancer Mutations with
Small-Molecule Stabilizers: the Y220X Paradigm
por: Bauer, Matthias R., et al.
Publicado: (2020) -
AI-powered discovery of a novel p53-Y220C reactivator
por: Zhou, Shan, et al.
Publicado: (2023)